SEARCH

SEARCH BY CITATION

References

  • 1
    Abiad H, Ramani R, Currie JB, Hershow RC, Abiad H, Ramani R, et al. The natural history of hepatitis D virus infection in Illinois state facilities for the developmentally disabled. Am J Gastroenterol 2001; 96: 534540.
    Direct Link:
  • 2
    Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006; 45: 197203.
  • 3
    Beasley RP, Hwang LY, Lin CC, Chien CS, Beasley RP, Hwang LY, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 11291133.
  • 4
    Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177182.
  • 5
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 6
    Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA, et al. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 2005; 34: 132137.
  • 7
    Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 17971803.
    Direct Link:
  • 8
    Chen JG, Kuang SY, Egner PA, Lu JH, Zhu YR, Wang JB, et al. Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007; 16: 12131218.
  • 9
    Crook PD, Jones ME, Hall AJ, Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003; 32: 118124.
  • 10
    Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT, et al. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369376.
  • 11
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBVSG, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678686.
  • 12
    Jee SH, Ohrr H, Sull JW, Samet JM, Jee SH, Ohrr H, et al. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004; 96: 18511856.
  • 13
    Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593601.
  • 14
    Lam CM, Chan AO, Ho P, Ng IO, Lo CM, Liu CL, et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening. Aliment Pharmacol Ther 2004; 19: 771777.
  • 15
    Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195: 511.
  • 16
    London WT, Evans AA, McGlynn K, Buetow K, An P, Gao L, et al. Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. Intervirology 1995; 38: 155161.
  • 17
    McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP, McMahon BJ, Alberts SR, et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 10511054.
  • 18
    McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. HEPATOLOGY 2000; 32: 842846.
  • 19
    McMahon BJ, Holck P, Bulkow L, Snowball M, McMahon BJ, Holck P, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759768.
  • 20
    Mori M, Hara M, Wada I, Hara T, Yamamoto K, Honda M, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000; 151: 131139.
  • 21
    Nomura A, Stemmermann GN, Chyou PH, Tabor E, Nomura A, Stemmermann GN, et al. Hepatitis B and C virus serologies among Japanese Americans with hepatocellular carcinoma. J Infect Dis 1996; 173: 14741476.
  • 22
    Norman JE, Beebe GW, Hoofnagle JH, Seeff LB, Norman JE, Beebe GW, et al. Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. HEPATOLOGY 1993; 18: 790797.
  • 23
    Ribes J, Cleries R, Rubio A, Hernandez JM, Mazzara R, Madoz P, et al. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006; 119: 687694.
  • 24
    Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. HEPATOLOGY 1995; 22: 432438.
  • 25
    Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H, Tanaka H, et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004; 112: 10751080.
  • 26
    Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 19211926.
  • 27
    Tokudome S, Ikeda M, Matsushita K, Maeda Y, Yoshinari M, Tokudome S, et al. Hepatocellular carcinoma among female Japanese hepatitis B virus carriers. Hepatogastroenterology 1987; 34: 246248.
  • 28
    Tong MJ, Blatt LM, Kao VW, Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16: 553559.
  • 29
    Tong MJ, Blatt LM, Tyson KB, Kao VWC. Death from liver disease and development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a prospective study. Gastroenterol Hepatol 2006; 2: 4147.
  • 30
    Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 66206626.
  • 31
    Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007; 27: 13561363.
  • 32
    Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14: 241250.
  • 33
    Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613616.
  • 34
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 35
    Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 10391047.
  • 36
    Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. HEPATOLOGY 1999; 29: 697702.
  • 37
    Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265272.
  • 38
    Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 16101614.
  • 39
    Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57: 9197.
  • 40
    Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921931.
  • 41
    Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008; 29: 106112.
  • 42
    Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 11341143.